BioLineRx (BLRX) Competitors $4.01 -0.12 (-2.91%) Closing price 07/30/2025 04:00 PM EasternExtended Trading$3.98 -0.03 (-0.75%) As of 07/30/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLRX vs. VRCA, ANRO, MGX, VTGN, ADAP, OTLK, SRZN, CELU, PYXS, and BMEAShould you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Verrica Pharmaceuticals (VRCA), Alto Neuroscience (ANRO), Metagenomi (MGX), VistaGen Therapeutics (VTGN), Adaptimmune Therapeutics (ADAP), Oncobiologics (OTLK), Surrozen (SRZN), Celularity (CELU), Pyxis Oncology (PYXS), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. BioLineRx vs. Its Competitors Verrica Pharmaceuticals Alto Neuroscience Metagenomi VistaGen Therapeutics Adaptimmune Therapeutics Oncobiologics Surrozen Celularity Pyxis Oncology Biomea Fusion BioLineRx (NASDAQ:BLRX) and Verrica Pharmaceuticals (NASDAQ:VRCA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership. Which has more risk and volatility, BLRX or VRCA? BioLineRx has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500. Comparatively, Verrica Pharmaceuticals has a beta of 1.76, meaning that its share price is 76% more volatile than the S&P 500. Do insiders and institutionals hold more shares of BLRX or VRCA? 1.6% of BioLineRx shares are owned by institutional investors. Comparatively, 42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. 1.1% of BioLineRx shares are owned by company insiders. Comparatively, 54.0% of Verrica Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Is BLRX or VRCA more profitable? Verrica Pharmaceuticals has a net margin of 0.00% compared to BioLineRx's net margin of -15.21%. Verrica Pharmaceuticals' return on equity of 0.00% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-15.21% -23.93% -6.80% Verrica Pharmaceuticals N/A N/A -145.63% Which has stronger valuation and earnings, BLRX or VRCA? BioLineRx has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$28.94M0.59-$9.22M-$8.80-0.46Verrica Pharmaceuticals$7.57M7.32-$76.58M-$12.00-0.50 Do analysts recommend BLRX or VRCA? BioLineRx presently has a consensus target price of $26.00, suggesting a potential upside of 548.38%. Verrica Pharmaceuticals has a consensus target price of $80.00, suggesting a potential upside of 1,235.56%. Given Verrica Pharmaceuticals' higher possible upside, analysts clearly believe Verrica Pharmaceuticals is more favorable than BioLineRx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Verrica Pharmaceuticals 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Does the media prefer BLRX or VRCA? In the previous week, Verrica Pharmaceuticals had 2 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Verrica Pharmaceuticals and 1 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.89 beat Verrica Pharmaceuticals' score of 0.99 indicating that BioLineRx is being referred to more favorably in the media. Company Overall Sentiment BioLineRx Very Positive Verrica Pharmaceuticals Positive SummaryBioLineRx and Verrica Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks. Get BioLineRx News Delivered to You Automatically Sign up to receive the latest news and ratings for BLRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLRX vs. The Competition Export to ExcelMetricBioLineRxMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.60M$2.51B$5.63B$9.53BDividend YieldN/A1.78%4.71%4.04%P/E Ratio-0.469.4930.2020.54Price / Sales0.59692.12455.8798.78Price / CashN/A159.7936.0158.40Price / Book0.994.968.345.74Net Income-$9.22M$31.62M$3.25B$259.12M7 Day Performance-11.09%-3.12%-2.15%-2.68%1 Month Performance-12.25%9.83%7.97%8.53%1 Year Performance-87.24%-5.59%36.49%14.91% BioLineRx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLRXBioLineRx3.0962 of 5 stars$4.01-2.9%$26.00+548.4%-86.8%$17.60M$28.94M-0.4640Positive NewsVRCAVerrica Pharmaceuticals4.4585 of 5 stars$0.77-5.8%$8.00+940.2%-91.0%$75.50M$7.57M0.0040ANROAlto Neuroscience2.3652 of 5 stars$2.74-1.5%$8.50+210.3%-77.5%$75.26MN/A0.00N/AMGXMetagenomi2.853 of 5 stars$2.17+9.0%$13.00+499.1%-43.3%$74.39M$52.29M0.00236Gap UpVTGNVistaGen Therapeutics0.4562 of 5 stars$2.55flatN/A-16.4%$74.35M$490K0.0040Positive NewsHigh Trading VolumeADAPAdaptimmune Therapeutics1.6977 of 5 stars$0.28-1.1%$1.35+388.8%-92.3%$74.08M$178.03M0.00490News CoverageAnalyst ForecastGap UpOTLKOncobiologics2.2577 of 5 stars$2.06-5.5%$9.60+366.0%-73.1%$73.18MN/A0.0020News CoverageSRZNSurrozen2.7156 of 5 stars$8.70+2.6%$38.50+342.5%+8.9%$72.61M$10.65M0.0080Positive NewsGap UpHigh Trading VolumeCELUCelularity0.137 of 5 stars$3.15+4.0%N/A+8.7%$72.57M$54.22M0.00220News CoveragePYXSPyxis Oncology2.3813 of 5 stars$1.13flat$9.00+696.5%-70.1%$70M$16.15M0.0060BMEABiomea Fusion3.1566 of 5 stars$1.83-1.1%$20.10+998.4%-68.8%$69.51MN/A0.0050Gap Up Related Companies and Tools Related Companies VRCA Competitors ANRO Competitors MGX Competitors VTGN Competitors ADAP Competitors OTLK Competitors SRZN Competitors CELU Competitors PYXS Competitors BMEA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BLRX) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioLineRx Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioLineRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLRX Stock Alerts